FDA Investigator Kathy E Craven
Kathy E Craven has conducted inspections on 5 sites in 2 countries as of 16 May 2002. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
5
Last Inspection Date:
16 May 2002
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Italy,
France
FDA Investigators that have inspected at least one site in common with Kathy E Craven:
Cary Greene,
Daniel J Lahar,
Douglas C Kovacs,
Felix Maldonado,
James A Lane,
Kathy E Noe,
Kevin A Gonzalez,
Leon L Law,
Marcellinus D Dordunoo,
Marie B Buen Bigornia,
Meisha R Sampson,
Michael E Maselli,
Michael Shanks, MS,
Mra Mcculloughj,
Nicole A Lloyd,
Patricia H Dlugosz,
Paul A Bonneau,
Paul L Figarole, Jr,
Ramon E Martinez,
Robert C Steyert,
Roy R Rinc,
Russell J Glapion,
Santos E Camara,
Satheesh Thomas,
Shirley J Berryman,
Steven C Madzo,
Steven M Weinman,
Susan P Bruederle,
Susanna E Ford,
Wayne E Seifert,
Wendy G Tan, PhD,
Xiaoping Guan,
Yasamin Ameri,
Yumi J Hiramine,
Zachary L Miller
Kathy E Craven's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2001 | FDA 483 Response | Sanofi Winthrop Industrie - Form 483R, 2001-12-17 |
May, 2002 | EIR | Lilly France - EIR, 2002-08-01 |
May, 2002 | EIR | Eli Lilly Italia SPA - EIR, 2002-08-01 |
May, 2002 | FDA 483 Response | Lilly France - Form 483R, 2002-05-30 |
May, 2002 | FDA 483 | ELI LILLY ITALIA S.p.A. - Form 483, 2002-05-24 |
November, 2001 | FDA 483 | Aventis Pharma Specialties - Form 483, 2001-11-27 |
November, 2001 | EIR | Sanofi Winthrop Industrie - EIR, 2001-11-27 |
May, 2002 | FDA 483 Response | Eli Lilly Italia SPA - Form 483R, 2002-05-24 |
May, 2002 | FDA 483 | Lilly France - Form 483, 2002-05-14 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more